Xenon Pharmaceuticals Inc. announced that it has entered into a share purchase agreement for a private placement of 275,337 common shares at a price of $19.9755 per share for gross proceeds of approximately $5,499,994 on September 8, 2021. The transaction will include participation from Neurocrine Biosciences, Inc. The purchase price represents a 15% premium to the company's 30-day volume-weighted average price immediately prior to the public announcement of the clinical trial application approval. The shares are subject to lock-up restriction.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.05 USD | -0.10% | -0.96% | -10.79% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.79% | 3.1B | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+3.17% | 22.19B | |
-16.16% | 21.33B | |
-7.10% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- XENE Stock
- News Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals Inc. announced that it expects to receive $5.499994 million in funding from Neurocrine Biosciences, Inc.